Eli Lilly and Company (LLY)
| Market Cap | 212.62B |
| Revenue (ttm) | 25.49B |
| Net Income (ttm) | 6.09B |
| Shares Out | 908.80M |
| EPS (ttm) | 6.68 |
| PE Ratio | 33.15 |
| Forward PE | 28.41 |
| Dividend | $3.07 |
| Dividend Yield | 1.39% |
| Trading Day | June 22 |
| Last Price | $221.44 |
| Previous Close | $222.67 |
| Change ($) | -1.23 |
| Change (%) | -0.55% |
| Day's Open | 222.63 |
| Day's Range | 220.51 - 223.61 |
| Day's Volume | 1,658,943 |
| 52-Week Range | 127.45 - 235.85 |
Buyers are rushing back in to the market after last week's rout. Here are the top stock trades to play right now.
By next summer we'll have enough vaccines to vaccinate the world: Eli Lilly CEO
Eli Lilly CEO David Ricks joins 'Influencers with Andy Serwer' to discuss global vaccine distribution. Watch the 2021 Berkshire Hathaway Annual Shareholders Meeting on YouTube: https://youtu.be/gx-OzwHpM9k
One is Biogen's partner. The other is a potential rival.
Eli Lilly CEO discusses COVID-19 treatments, and Biogen's FDA approval of new Alzheimer's drug
In this episode of Influencers, Eli Lilly Chairman & CEO David Ricks joins Andy to discuss the latest in the pharmaceutical industry, new progress in the fight against COVID-19, and potential groundbrea...
Microsoft, Twilio, Eli Lilly and General Electric were our top stock trades for Monday. Let's look at how the charts are setting up now.
We think that Pfizer currently is a better pick compared to Eli Lilly & Company. PFE stock trades at about 5x trailing revenues, compared to around 8x for LLY.
In the latest trading session, Eli Lilly (LLY) closed at $222.21, marking a +0.66% move from the previous day.
INDIANAPOLIS, June 17, 2021 /PRNewswire/ -- Based on results from a large population-based survey, it is estimated that approximately half of people with migraine hesitate to seek care for a variety of ...
Eli Lilly CEO discusses FDA's approval of Biogen's new Alzheimer's drug
Eli Lilly CEO David Ricks joins 'Influencers with Andy Serwer' to discuss the FDA's approval of Biogen's new Alzheimer's drug. Watch the 2021 Berkshire Hathaway Annual Shareholders Meeting on YouTube: h...
All the major indexes pulled back on Tuesday, with the Nasdaq leading the charge. Despite this, crude oil jumped back above $72 a barrel, and Bitcoin was fairly stagnant at $40,000.
Eli Lilly And Co (NYSE: LLY) will conduct a head-to-head study comparing once-monthly injectable Emgality (galcanezumab-gnlm) with Biohaven Pharmaceutical Holding Co Ltd's (NYSE: BHVN) Nurtec ODT (rimeg...
INDIANAPOLIS, June 15, 2021 /PRNewswire/ -- To advance the science of migraine treatment and aid the understanding of calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) compared to oral...
INDIANAPOLIS, June 14, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Guggenheim Biopharma Strategy Series – Biopharma's Next Decade: Views from the Top on Global Strateg...
Eli Lilly and Co (NYSE: LLY) revealed last month that the U.S. Department of Justice (DOJ) issued a subpoena into its manufacturing facility in Branchburg, New Jersey, but the company has already finish...
INDIANAPOLIS, June 11, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will host a webcast on Thursday, July 1, 2021 to discuss the company's diabetes portfolio and its presentations at the Ameri...
The FDA's approval of Biogen's Aduhelm in treating Alzheimer's disease boosted all three stocks.
A week before Eli Lilly disclosed to regulators that the U.S. Justice Department was investigating its New Jersey factory, the drugmaker told employees that its own inquiry, led by an outside law firm, ...
Eli Lilly And Co. (NYSE:LLY) shares are up nearly 12% this week after the Food and Drug Administration (FDA) approved Biogen Inc.'s (NASDAQ:BIIB) Alzheimer's drug, aducanumab marketed under the brand na...
Now that Biogen Inc.'s ( BIIB , Financial) Alzheimer's treatment has received the Food and Drug Administration's approval, who's next?
The stock price of Eli Lilly & Company (NYSE: LLY) has seen a large 10% rise in a single trading session yesterday. This move came after Biogen's Aduhelm was approved by the U.S. FDA for the treatment o...
FDA approves Biogen's (BIIB) Alzheimer's disease ("AD") drug, Aduhelm (aducanumab). Stocks of Eli Lilly (LLY), Cassava Sciences (SAVA) and Annovis Bio (ANVS) rise as they also have AD candidates in thei...
Biogen's stunning win of FDA approval for aducanumab spurred investors' excitement about Lilly's prospects for its Alzheimer's disease candidate.
Eli Lilly (LLY) closed the most recent trading day at $202.02, moving -0.34% from the previous trading session.
INDIANAPOLIS, June 4, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data for the investigational use of Verzenio® (abemaciclib) in high risk early breast cancer, and for its...
INDIANAPOLIS, June 3, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Goldman Sachs Healthcare Conference on June 9 and 10, 2021. Anne White, senior vice president and pre...
The National Medical Products Administration (NMPA) of China has approved Innovent Biologics Inc (OTC: IVBXF) and Eli Lilly And Co's (NYSE: LLY) Tyvyt (sintilimab injection) in non-small cell lung cance...
INDIANAPOLIS, June 3, 2021 /PRNewswire/ -- To improve the understanding and advance the treatment of migraine, Eli Lilly and Company (NYSE: LLY) presented data on unmet needs in migraine from the OVERCO...
SAN FRANCISCO and SUZHOU, China, June 3, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes hi...
Eli Lilly And Co (NYSE: LLY) has reported posthoc analyses data from the Phase 3 RA-BEAM study that showed Olumiant 4mg (baricitinib) lowered pain and duration of morning joint stiffness in moderate to ...
INDIANAPOLIS, June 1, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) will present data from post-hoc analyses that suggested OLUMIANT® (baricitinib) 4 mg tablet reduced...
INDIANAPOLIS, June 1, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present new data from Phase 3 studies that further demonstrated the long-term efficacy and safety profile of Taltz® (ixe...
The U.S. Justice Department has launched a criminal investigation into Eli Lilly and Co (NYSE: LLY) focused on alleged manufacturing irregularities and records tampering at Branchburg plant, reports Reu...
The U.S. Justice Department has launched a criminal investigation into Eli Lilly and Co focused on alleged manufacturing irregularities and records tampering at a factory in Branchburg, New Jersey, that...
Lilly (LLY) reported earnings 30 days ago. What's next for the stock?
Eli Lilly and Co (NYSE: LLY) has received a subpoena from the U.S. Department of Justice related to its New Jersey plant that makes its COVID-19 treatment, bamlanivimab, reports Reuters. The subpoena re...
AFYA, BNL, CLBS, EKSO, and LLY have been added to the Zacks Rank #5 (Strong Sell) List on May 27, 2021
Eli Lilly and Co has received a subpoena from the U.S. Department of Justice, requesting certain documents relating to its manufacturing site in Branchburg, New Jersey, the drugmaker said in a filing on...
Getting rich is as simple as buying and holding for the long haul.
Lilly (LLY) and Innovent's sintilimab, a PD-1 inhibitor, is marketed by the brand name of Tyvyt in China for two indications.
Capital is flowing once more into healthcare stocks. These companies are three of the best components of the sector for investors to buy now.
As a part of a pre-specified analysis of the Phase 2 SERENITY study, new data showed that Eli Lilly And Co's (NYSE: LLY) mirikizumab improved fatigue in patients with moderately to severely active Crohn...
If you are looking for investment opportunities among U.S.-listed equities, you may want to consider the stocks listed below, as they have seen their free cash flow (FCF) grow remarkably over recent yea...
INDIANAPOLIS, May 22, 2021 /PRNewswire/ -- In a pre-specified analysis of the Phase 2 SERENITY study, Eli Lilly and Company's (NYSE: LLY) mirikizumab improved fatigue in patients with moderately to seve...
Lilly's (LLY) SURPASS-4 study evaluating tirzepatide against insulin glargine in adults with type 2 diabetes and increased cardiovascular risk meets all primary and key secondary endpoints.
Eli Lilly and Co (NYSE: LLY) has reported topline data from Phase 3 SURPASS-4 clinical trial evaluating tirzepatide in adults with type 2 diabetes and increased cardiovascular risk. Measuring the GLP-1 ...
INDIANAPOLIS, May 20, 2021 /PRNewswire/ -- Tirzepatide led to superior A1C and body weight reductions from baseline across all three doses in adults with type 2 diabetes who have increased cardiovascula...
INDIANAPOLIS, May 19, 2021 /PRNewswire/ -- New data from across Eli Lilly and Company's (NYSE: LLY) oncology portfolio will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual M...
ALBO, BFIN, GOOS, DKNG, and LLY have been added to the Zacks Rank #5 (Strong Sell) List on May 19, 2021
Here are seven biotech stocks with loads of innovation and plenty of catalysts to make money for smart investors. The post 7 Best Biotech Stocks To Buy in 2021 as Innovation Takes Center Stage appeared ...
About LLY
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesotheli... [Read more...]
| Industry Drug Manufacturers-General | Founded 1876 |
| CEO David Ricks | Employees 34,690 |
| Stock Exchange NYSE | Ticker Symbol LLY |
Financial Performance
In 2020, Eli Lilly's revenue was $24.54 billion, an increase of 9.95% compared to the previous year's $22.32 billion. Earnings were $6.19 billion, a decrease of -25.54%.
Analyst Forecasts
According to 20 analysts, the average rating for Eli Lilly stock is "Buy." The 12-month stock price forecast is 218.25, which is a decrease of -1.44% from the latest price.